mthfr glutathione supplementation and – Methyl-Life® Supplements methylation B complex+ - 1
Description
10.1111/phpp.12679 130 TelloT
The success of these efforts relies on establishing robust end points, incorporating technology, and identifying reliable biomarkers for early diagnosis and continuous monitoring of disease progression
F., Medeiros, M
In the GARNET study, 104 patients with EC who had progressed after at least 1 line of chemotherapy were treated with dostarlimab, a PD-1 inhibitor, with an ORR of 42.3%, disease control rate (DCR) of 57.7%, and mPFS of 8.1 months (95% CI 3.018)
